Molecular profiling of lung carcinoma: identifying clinically useful tumor markers for diagnosis and prognosis

被引:15
作者
Dacic, Sanja [1 ]
机构
[1] Univ Pittsburgh, Ctr Med, Dept Pathol, Pittsburgh, PA 15213 USA
关键词
diagnosis; lung cancer; molecular markers; prognosis;
D O I
10.1586/14737159.7.1.77
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The overall survival of patients with lung cancer is dismal despite extensive effort in improvement of diagnosis and treatment. A better understanding of the multistep genetic and epigenetic alterations in lung cancer pathogenesis and progression is necessary for development of improved diagnostic approaches and new targeted therapies. Identification of molecular alterations in the early lung carcinogenesis, together with advanced molecular techniques, may facilitate development of rapid and effective methods for early diagnosis and prognosis of lung carcinoma. In this review, we discuss current understanding of lung carcinogenesis and prospective molecular markers in lung cancer diagnosis. Although the impact of translating new technologies into clinical practice on survival has not been completely determined, they offer a new avenue of exciting novel approaches to early diagnosis of this deadly disease.
引用
收藏
页码:77 / 86
页数:10
相关论文
共 80 条
[11]   Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer [J].
Cappuzzo, F ;
Magrini, E ;
Ceresoli, GL ;
Bartolini, S ;
Rossi, E ;
Ludovini, V ;
Gregorc, V ;
Ligorio, C ;
Cancellieri, A ;
Damiani, S ;
Spreafico, A ;
Paties, CT ;
Lombardo, L ;
Calandri, C ;
Bellezza, G ;
Tonato, M ;
Crinò, L .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (15) :1133-1141
[12]   Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial [J].
Cella, D ;
Herbst, RS ;
Lynch, TJ ;
Prager, D ;
Belani, CP ;
Schiller, JH ;
Heyes, A ;
Ochs, JS ;
Wolf, MK ;
Kay, AC ;
Kris, MG ;
Natale, RB .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (13) :2946-2954
[13]   The association between atypical adenomatous hyperplasia and primary lung cancer [J].
Chapman, AD ;
Kerr, KM .
BRITISH JOURNAL OF CANCER, 2000, 83 (05) :632-636
[14]  
Chmara M, 2004, ANTICANCER RES, V24, P4259
[15]   Role of FHIT in human cancer [J].
Croce, CM ;
Sozzi, G ;
Huebner, K .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) :1618-1624
[16]   A biologic risk model for stage I lung cancer: Immunohistochemical analysis of 408 patients with the use of ten molecular markers [J].
D'Amico, TA ;
Massey, M ;
Herndon, JE ;
Moore, MB ;
Harpole, DH .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1999, 117 (04) :736-742
[17]   Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3 [J].
Dammann, R ;
Li, C ;
Yoon, JH ;
Chin, PL ;
Bates, S ;
Pfeifer, GP .
NATURE GENETICS, 2000, 25 (03) :315-319
[18]   K-ras and p16INK4A alterations in sputum of NSCLC patients and in heavy asymptomatic chronic smokers [J].
Destro, A ;
Bianchi, P ;
Alloisio, M ;
Laghi, L ;
Di Gioia, S ;
Malesci, A ;
Cariboni, U ;
Gribaudi, G ;
Bulfamante, G ;
Marchetti, A ;
Bosari, S ;
Infante, M ;
Ravasi, G ;
Roncalli, M .
LUNG CANCER, 2004, 44 (01) :23-32
[19]   Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction [J].
Endoh, H ;
Tomida, S ;
Yatabe, Y ;
Konishi, H ;
Osada, H ;
Tajima, K ;
Kuwano, T ;
Takahashi, T ;
Mitsudomi, T .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :811-819
[20]   Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J].
Fukuoka, M ;
Yano, S ;
Giaccone, G ;
Tamura, T ;
Nakagawa, K ;
Douillard, JY ;
Nishiwaki, Y ;
Vansteenkiste, J ;
Kudoh, S ;
Rischin, D ;
Eek, R ;
Horai, T ;
Noda, K ;
Takata, I ;
Smit, E ;
Averbuch, S ;
Macleod, A ;
Feyereislova, A ;
Dong, RP ;
Baselga, J .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2237-2246